Coformulated vibostolimab/pembrolizumab in advanced cervical cancer: KEYVIBE-005

Association of biomarkers with response to coformulated vibostolimab/pembrolizumab (vibo/pembro) in metastatic cervical cancer (CC): exploratory analysis from the phase 2 KEYVIBE-005 study

A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab in Patients with High-Risk, Locally Advanced, Cervical Cancer (KEYNOTE-A18/ENGOT-cx11/GOG-3047): Results for Patients Enrolled in Asia

Safety and Efficacy Results in Patients Who Received Dose Modifications in the Phase 3 MIRASOL (GOG 3045/ENGOT-ov55) Trial of Mirvetuximab Soravtansine vs Investigator's Choice Chemotherapy (ICC) in Platinum-Resistant Ovarian Cancer (PROC) with High Folate Receptor-Alpha Expression

Quality-Adjusted Survival in patients with advanced or recurrent endometrial carcinoma treated with atezolizumab in combination with carboplatin-paclitaxel versus carboplatin-paclitaxel in the AtTEnd/ENGOT-EN7 Trial

Patient-reported outcomes in primary advanced or recurrent endometrial carcinoma treated with atezolizumab or placebo in combination with carboplatin-paclitaxel in the AtTEnd/ENGOT-EN7 Trial

Dostarlimab plus chemotherapy in primary advanced or recurrent endometrial cancer (pA/rEC) in the RUBY trial: overall survival (OS) by MMR status and molecular subgroups

Phase 3 ENGOT-En9/LEAP-001 Study: Lenvatinib + Pembrolizumab (LEN/PEMBRO) vs Chemotherapy (Chemo) as First-Line (1L) Therapy for Advanced or Recurrent Endometrial Cancer

Updated progression-free survival (PFS) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) treated with rucaparib (RUC) in ATHENA-MONO